Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.4052W HIGH $12.25
Volume
358.85 K
Value Traded
816.28 K
Short % Float
4.22%
-7.49%Week
-3.89%1 Month
-6.99%3 Month
-76.72%6 Month
-78.93%5 Year
-79.42%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
115.94 M
EPS (TTM)
-1.95
P/E Ratio
-
Ent. Value
-150.38 M
Total Shares
66.98 M
Float Shares
28.44 M
Insiders
57.56%
Institutions
43.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ENGN Catalyst Timeline
Dated clinical, regulatory and corporate events for enGene Holdings Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for enGene Holdings Inc.
135Total events
13Upcoming
35Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompletedetalimogeneFiledTrial
Detalimogene plus surfactant cohort safety run-in successfully cleared
BCG-unresponsive NMIBC with CISsource ↗
●R&D DayPresentation
Emerging NMIBC Market Insights KOL Webinar
non-muscle invasive bladder cancer (NMIBC)source ↗
◆Topline ReadoutdetalimogeneFiledClinical Data
12-month complete response data from LEGEND pivotal cohort
high-risk, BCG-unresponsive non-muscle invasive bladder cancer with CISsource ↗
●BLA SubmissiondetalimogeneFiledRegulatory Filing
BLA submission for detalimogene
high-risk, BCG-unresponsive non-muscle invasive bladder cancer with CISsource ↗
◆Full ResultsdetalimogeneFiledClinical Data
12-month complete response data for all of Cohort 1 expected
high-risk BCG-unresponsive NMIBC with CISsource ↗
◆Timing Guidancedetalimogene voraplasmidFiledPresentation
Anticipated BLA filing for detalimogene in mid-2026
high-risk, BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situsource ↗
▲First Patient DoseddetalimogeneFiledTrial
First patients enrolled in detalimogene plus surfactant cohort
BCG-unresponsive NMIBC with CISsource ↗
▼Trial DiscontinueddetalimogeneFiledTrial
Enrollment stopped in LEGEND Cohorts 2a, 2b, and 3 due to cash conservation
NMIBCsource ↗
●Timing GuidancedetalimogeneFiledPresentation
BLA filing for detalimogene on track for mid-2026
BCG-unresponsive NMIBC with CISsource ↗
●BLA SubmissionEG-70FiledRegulatory Filing
BLA submission for EG-70
BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC)source ↗
◆Oral Presentationdetalimogene voraplasmidFiledPresentation
Plenary Presentation at American Urological Association meeting
high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situsource ↗
◆Topline Readoutdetalimogene voraplasmidFiledClinical Data
Updated interim results from LEGEND pivotal cohort
high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situsource ↗
◆Oral PresentationdetalimogeneFiledPresentation
Plenary presentation of interim data from LEGEND Cohort 1 at AUA meeting
high-risk BCG-unresponsive NMIBC with CISsource ↗
●Timing GuidancedetalimogeneFiledPresentation
Planned BLA submission for detalimogene
high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with CISsource ↗
◆Timing Guidancedetalimogene voraplasmidFiledPresentation
Update on BLA filing plans in second half of 2026
high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situsource ↗
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Fireside Chat
◆Oral PresentationPresentation
Leerink Partners 2026 Global Healthcare Conference Fireside Chat
◆Oral PresentationdetalimogeneFiledPresentation
LEGEND pivotal cohort update at spring medical conference
high-risk, BCG-unresponsive non-muscle invasive bladder cancer with CISsource ↗
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference Presentation
◆Oral PresentationPresentation
enGene participates in Guggenheim Emerging Outlook: Biotech Summit 2026 fireside chat
▲Debt Royalty FinancingCorporate
Expanded debt facility with Hercules Capital for up to $125 million
▲Enrollment CompletedetalimogeneFiledTrial
Completed enrollment in LEGEND pivotal cohort with 125 patients
high-risk, BCG-unresponsive NMIBC with carcinoma in situsource ↗
▲Manufacturing Milestonedetalimogene voraplasmidFiledCMC / Inspection
Selected for FDA CMC Development and Readiness Pilot (CDRP) Program
high-risk, non-muscle invasive bladder cancersource ↗
▲Manufacturing MilestonedetalimogeneFiledCMC / Inspection
Detalimogene selected for FDA CDRP program
▼Equity OfferingCorporate
Pricing of $130 million public offering of common shares and pre-funded warrants
◆Oral Presentationdetalimogene voraplasmidFiledPresentation
Conference call to discuss new preliminary data from pivotal cohort of LEGEND trial
high-risk, BCG-unresponsive non-muscle invasive bladder cancersource ↗
▲Topline Readoutdetalimogene voraplasmidFiledClinical Data
Positive preliminary results from LEGEND pivotal cohort: 62% CR at 6 months
high-risk, BCG-unresponsive NMIBC with CISsource ↗
▲Topline ReadoutdetalimogeneFiledClinical Data
Positive preliminary results from LEGEND pivotal cohort: 62% CR at 6 months
high-risk, BCG-unresponsive NMIBC with CISsource ↗
▲Enrollment CompletedetalimogeneFiledTrial
Enrollment completed for LEGEND pivotal cohort (125 patients)
high-risk, BCG-unresponsive non-muscle invasive bladder cancer with CISsource ↗
▲Interim AnalysisdetalimogeneFiledTrial
Preliminary data from LEGEND pivotal cohort (post-amendment patients)
high-risk, BCG-unresponsive non-muscle invasive bladder cancer with CISsource ↗
▼Equity OfferingCorporate
Public offering of common shares and pre-funded warrants ($140.1M net proceeds)
●Enrollment UpdatedetalimogeneFiledTrial
Cohort 2b enrollment: 45 patients
high-risk NMIBC with CIS, BCG-exposed inadequatesource ↗
◆Topline ReadoutdetalimogeneFiledClinical Data
Updated preliminary data from LEGEND trial's pivotal cohort
high-risk BCG-unresponsive NMIBC with carcinoma in situsource ↗
◆Oral PresentationdetalimogeneFiledPresentation
Trial in progress updates from LEGEND additional cohorts (Cohorts 2a, 2b, 3)
HR-NMIBC with CIS (BCG-naive, BCG-exposed, BCG-unresponsive papillary-only)source ↗
▲Enrollment CompletedetalimogeneFiledTrial
Target enrollment reached in detalimogene's pivotal NMIBC clinical trial
high-risk, BCG-unresponsive NMIBC with CISsource ↗
▲Enrollment CompletedetalimogeneFiledTrial
Achieved target enrollment milestone of 100 patients for LEGEND pivotal cohort
high-risk BCG-unresponsive NMIBC with carcinoma in situsource ↗
Past FDA Catalysts and PDUFA Decisions
How ENGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | Detalimogene voraplasmid (also known as detalimogene, previously EG-70) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$59M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.5x
rNPV / MCap
Top 47%
Micro Cap(rank 311 of 660)
Percentile Rank
enGene Holdings Inc. faces pipeline headwinds (37/100), with $234M risk-adjusted pipeline value, led by EG-70 in Superficial Bladder Cancer (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EG-70 Small moleculeNCT04752722 | Superficial Bladder Cancer | Phase 2 | RECRUITING | 350 | Nov 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every ENGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| detalimogene voraplasmid | high-risk non-muscle invasive bladder cancer (NMIBC) | Phase 2 | 2026-05-07 | complete response rate any time: 54%; complete response rate 6 months: 43%; progression rate: 3.2%; duration of response: 25%; median duration of response weeks: 37.3 weeksRead More | enGene Announces Updated Interim Results From LEGEND Pivotal CohortRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Grossman WilliamDirector, Officer (Interim Chief Medical Officer) | Buy | 5,102 5,102 held | $1.97 | 09/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ENGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.8 % (-11.1 %) | 39.69 M | 5.83 M | -0.71% ( -41.57 K) |
ENGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ENGN ranks across every disease it competes in
Competitive Position is a premium feature
See how ENGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialENGN News
ENGN▲ +5.5%on this news
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
enGene Therapeutics Inc. reported its financial results for Q3 2026, highlighting progress in its clinical programs. The company is focusing on maturing regulatory endpoints data from its pivotal cohort and plans to engage with the FDA regarding a Biologics License Application for detalimogene. This update reflects enGene's ongoing commitment to advancing its genetic medicine initiatives.
Read more →ENGNenGene to Participate in Upcoming Investor Conferences
enGene Therapeutics Inc. has announced its participation in two upcoming investor conferences. The Wells Fargo 21st Annual Healthcare Conference will take place on September 8, 2026, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. These events will feature management in a fireside chat format, aiming to connect with investors.
Read more →ENGNenGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
enGene Therapeutics Inc. will host a virtual key opinion leader event on August 11, 2026, focusing on the non-muscle invasive bladder cancer (NMIBC) market. Dr. Neal Shore will provide insights into the treatment landscape, showcasing the company's commitment to advancing genetic medicine. This event aims to enhance understanding of NMIBC considerations.
Read more →ENGNenGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
enGene Therapeutics Inc. has announced changes to its Board of Directors to enhance support for upcoming regulatory milestones and commercial readiness for its product detalimogene voraplasmid. This product is currently under evaluation in the Phase 2 LEGEND trial, which aims to establish its safety and efficacy in high-risk patients. The company's strategic focus indicates a proactive approach to potential market entry.
Read more →ENGN▲ +9.3%on this news
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
enGene has reported its financial results for the second quarter of 2026 and provided a business update. However, the article lacks specific details regarding the financial performance or business developments. The information presented is minimal and does not elaborate on any significant changes or outcomes.
Read more →ENGN▼ -80.6%on this news
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
enGene Therapeutics has reported updated interim results from the Phase 2 LEGEND trial of detalimogene voraplasmid for high-risk NMIBC patients. The trial showed a 54% complete response rate at any time and a low progression rate to muscle-invasive disease. While the treatment was generally well tolerated, durability outcomes were not as expected, prompting further evaluation.
Read more →ENGNenGene Announces Name Change to enGene Therapeutics Inc.
enGene has announced a name change to enGene Therapeutics Inc. This rebranding reflects the company's focus on therapeutic development. The announcement is part of a broader strategy to enhance its market presence and align its identity with its mission.
Read more →ENGN▼ -18.8%on this news
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
enGene Holdings Inc. reported its first quarter 2026 financial results, highlighting a strong cash position and plans for a Biologics License Application (BLA) submission for detalimogene in the second half of 2026. The company anticipates presenting data from its LEGEND pivotal cohort at a spring medical conference. Despite an increase in net loss, enGene remains optimistic about the potential of detalimogene for treating high-risk bladder cancer.
Read more →ENGNenGene to Participate in Upcoming Investor Conferences - February 20, 2026
enGene Holdings Inc. announced its participation in several upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Barclays 28th Annual Global Healthcare Conference. The company is focused on developing genetic medicines, particularly its lead program for Non-Muscle Invasive Bladder Cancer. These events will provide opportunities for management to engage with investors and discuss their ongoing clinical trials.
Read more →ENGN▼ -7.6%on this news
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
enGene Holdings Inc. announced that CEO Ron Cooper will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. The event is scheduled for February 11, 2026, and will be accessible via a live webcast. enGene is advancing genetic medicines, particularly its lead program for Non-Muscle Invasive Bladder Cancer.
Read more →ENGNenGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
enGene Holdings Inc. has announced an expanded debt facility of up to $125 million with Hercules Capital. The funding will support the development and commercialization of detalimogene voraplasmid for treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The company plans to file a Biologics License Application with the FDA in the second half of 2026.
Read more →ENGNenGene Reports Full Year 2025 Financial Results and Provides Business Update
enGene Holdings Inc. reported its financial results for the full year ended October 31, 2025, highlighting several significant milestones. The company completed enrollment in its pivotal LEGEND cohort with 125 patients and reported a 6-month complete response rate of 62%. enGene has also been selected for the FDA's CDRP Program, which aids in chemistry, manufacturing, and controls development. However, despite these developments, the company faced a net loss of approximately $117.3 million due to increased operating expenses.
Read more →ENGNenGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
enGene Holdings Inc. announced that its investigational gene therapy, detalimogene voraplasmid, has been selected by the FDA for the CMC Development and Readiness Pilot Program. This program aims to enhance manufacturing readiness for therapies with compressed clinical timelines. The company also reported promising results from the LEGEND trial, showing a 62% complete response rate in patients with high-risk NMIBC.
Read more →ENGNenGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
enGene Holdings Inc. has announced the pricing of its public offering, which aims to raise $130 million by offering 12,558,823 common shares at $8.50 each and pre-funded warrants at $8.4999 each. The company's public offering is set to close on or about November 14, 2025, pending customary closing conditions. The additional funds raised will further support the firm's clinical programs, particularly its lead candidate aimed at non-muscle invasive bladder cancer. Jefferies, Leerink Partners, and Wells Fargo Securities are among the firms managing the offering.
Read more →ENGNenGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
enGene Holdings Inc. will host a conference call on November 11, 2025, to discuss preliminary data from the pivotal cohort of its LEGEND trial. The trial focuses on its gene therapy candidate, detalimogene voraplasmid, targeted at patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. This represents a significant step in the development of therapies addressing a high clinical need within this patient population.
Read more →ENGN▲ +5.9%on this news· ran to +20% by day 3
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy
enGene Holdings Inc. has appointed Dr. Hussein Sweiti as Chief Medical Officer, effective September 29, 2025. Dr. Sweiti brings extensive experience in oncology clinical research and regulatory submissions, having recently led successful FDA interactions for bladder cancer treatments at Johnson & Johnson. His appointment aims to enhance enGene's clinical development and regulatory capacity in preparation for the expected BLA submission for detalimogene, an investigational treatment for high-risk non-muscle invasive bladder cancer, anticipated in the second half of 2026.
Read more →About enGene Holdings Inc.
Headquarters4868 RUE LEVY, SUITE 220, SAINT-LAURENT
BIOPHARMAWATCH ELITE PLUS
Trade the next ENGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime